LOGIN
WCO-IOF: Rituximab for rheumatoid arthritis positively impacts BMD of femoral neck
April 2014
WCO-IOF: Rituximab for rheumatoid arthritis positively impacts BMD of femoral neck
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
92 patients diagnosed with rheumatoid arthritis (RA) were randomized to receive methotrexate with or without rituximab therapy to assess the impact of rituximab treatment on bone mineral density (BMD) at the femoral neck. BMD and T-scores significantly increased after 3 years in patients who received methotrexate and rituximab therapy, and maintained positive trends at the 4-year follow-up. No sig...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.